Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers

Hatsushi Yamagishi; Tomoyuki Koike; Shuichi Ohara; Toru Horii; Ryousuke Kikuchi; Shigeyuki Kobayashi; Yasuhiko Abe; Katsunori Iijima; Akira Imatani; Kaori Suzuki; Takanori Hishinuma; Junichi Goto; Tooru Shimosegawa

doi:10.3748/wjg.14.2049

Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers

Hatsushi Yamagishi, Tomoyuki Koike, Shuichi Ohara, Toru Horii, Ryousuke Kikuchi, Shigeyuki Kobayashi, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Kaori Suzuki, Takanori Hishinuma, Junichi Goto, Tooru Shimosegawa

Tohoku University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Aim: To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose. Methods: Eight H pylori-negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug. Results: LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study. Conclusion: In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.

Original language	English
Pages (from-to)	2049-2054
Number of pages	6
Journal	World Journal of Gastroenterology
Volume	14
Issue number	13
DOIs	https://doi.org/10.3748/wjg.14.2049
Publication status	Published - 2008 Apr 7

Keywords

Blood drug concentration
Cytochrome P450 2C19 extensive metabolizers
H pylori-negative
Intragastric pH
LPZ 30 mg orally disintegrating tablets

Access to Document

10.3748/wjg.14.2049

Cite this

Yamagishi, H., Koike, T., Ohara, S., Horii, T., Kikuchi, R., Kobayashi, S., Abe, Y., Iijima, K., Imatani, A., Suzuki, K., Hishinuma, T., Goto, J., & Shimosegawa, T. (2008). Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers. World Journal of Gastroenterology, 14(13), 2049-2054. https://doi.org/10.3748/wjg.14.2049

@article{a729edaeeffc4eb8867e5ba6c1fcc65e,

title = "Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers",

abstract = "Aim: To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose. Methods: Eight H pylori-negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug. Results: LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study. Conclusion: In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.",

keywords = "Blood drug concentration, Cytochrome P450 2C19 extensive metabolizers, H pylori-negative, Intragastric pH, LPZ 30 mg orally disintegrating tablets",

author = "Hatsushi Yamagishi and Tomoyuki Koike and Shuichi Ohara and Toru Horii and Ryousuke Kikuchi and Shigeyuki Kobayashi and Yasuhiko Abe and Katsunori Iijima and Akira Imatani and Kaori Suzuki and Takanori Hishinuma and Junichi Goto and Tooru Shimosegawa",

year = "2008",

month = apr,

day = "7",

doi = "10.3748/wjg.14.2049",

language = "English",

volume = "14",

pages = "2049--2054",

journal = "World Journal of Gastroenterology",

issn = "1007-9327",

publisher = "Baishideng Publishing Group",

number = "13",

}

Yamagishi, H, Koike, T, Ohara, S, Horii, T, Kikuchi, R, Kobayashi, S, Abe, Y, Iijima, K, Imatani, A, Suzuki, K, Hishinuma, T, Goto, J & Shimosegawa, T 2008, 'Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers', World Journal of Gastroenterology, vol. 14, no. 13, pp. 2049-2054. https://doi.org/10.3748/wjg.14.2049

TY - JOUR

T1 - Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers

AU - Yamagishi, Hatsushi

AU - Koike, Tomoyuki

AU - Ohara, Shuichi

AU - Horii, Toru

AU - Kikuchi, Ryousuke

AU - Kobayashi, Shigeyuki

AU - Abe, Yasuhiko

AU - Iijima, Katsunori

AU - Imatani, Akira

AU - Suzuki, Kaori

AU - Hishinuma, Takanori

AU - Goto, Junichi

AU - Shimosegawa, Tooru

PY - 2008/4/7

Y1 - 2008/4/7

N2 - Aim: To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose. Methods: Eight H pylori-negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug. Results: LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study. Conclusion: In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.

AB - Aim: To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose. Methods: Eight H pylori-negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug. Results: LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study. Conclusion: In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.

KW - Blood drug concentration

KW - Cytochrome P450 2C19 extensive metabolizers

KW - H pylori-negative

KW - Intragastric pH

KW - LPZ 30 mg orally disintegrating tablets

UR - http://www.scopus.com/inward/record.url?scp=44849126313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849126313&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.2049

DO - 10.3748/wjg.14.2049

M3 - Article

C2 - 18395905

AN - SCOPUS:44849126313

SN - 1007-9327

VL - 14

SP - 2049

EP - 2054

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

IS - 13

ER -

Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this